Form 4: Haemonetics Director Mark W. Kroll Acquires 2,207 Restricted Stock Units

Director Mark W. Kroll reports acquisition of 2,207 restricted stock units in Haemonetics Corp.

Summary

• On July 25, 2024, Mark W. Kroll, a director of Haemonetics Corp, acquired 2,207 restricted stock units (RSUs).
• These RSUs were issued under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs vest 100% on the first anniversary of the grant date.
• Each RSU represents the right to receive one share of Haemonetics Corp's common stock upon vesting.
• Following the transaction, Kroll directly owns 20,664 shares of Haemonetics Corp.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock units acquisition by a director, indicating alignment with company performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest 100% on the first anniversary of the grant date, indicating a future event tied to the company's stock.

Industry Context

This is a standard disclosure related to executive compensation and is common in publicly traded companies.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder confidence.

Key Dates